Innovation in Value Assessment ICER's recent launch of an updated Value Assessment Framework indicates their focus on refining health technology assessments with updated methodologies, presenting opportunities to partner on advanced evaluation tools or to integrate innovative pricing models aligned with their framework.

Engagement in Rare Diseases The organization's active evaluation of gene therapies for sickle cell disease and innovative treatments for Alzheimer’s demonstrates a strategic interest in high-impact, complex medical conditions, offering sales prospects for targeted diagnostic, monitoring, or supporting therapeutic solutions.

Technology Collaboration Potential ICER utilizes various modern tech stacks including AWS, Stripe, and Google Tag Manager, showcasing openness to tech integrations and collaborations—an opening for providers offering health tech innovations, data analytics, or platform integrations.

Growing Evidence Reports Regular production of comprehensive evidence reports on new drugs and therapies suggests a demand for advanced clinical data services, evidence generation tools, or consulting services that can enhance or streamline their review processes.

Partnership Opportunities ICER’s recent partnerships, such as with Peterson Health Technology Institute, highlight opportunities for collaborative projects in digital health, electronic health tools, and patient engagement platforms, presenting avenues for strategic alliances or product integration.